The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 to 2028.
North American market for PEGylated proteins is expected to grow from $3.7 billion in 2023 and projected to reach $5.6 billion by the end of 2028, at a CAGR of 8.9% during the forecast period of 2023 to 2028.
The European market for PEGylated proteins is expected to grow from $3.2 billion in 2023 and projected to reach $5.1 billion by the end of 2028, at a CAGR of 9.5% during the forecast period of 2023 to 2028.
Report Scope
This report highlights the current and future market potential of PEGylated proteins and provides a detailed analysis of the drivers, restraints, and opportunities in this market. The report also surveys the competitive environment for PEGylated proteins, including coverage of the pipeline activities adopted by players in this market, and it includes market projections for 2028. Also included are company profiles of key players featuring detailed information about each company's business segments, financials, product portfolios and recent developments. The report does not cover PEGylated vaccines.
In this report, the global market for PEGylated proteins market is segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World. For market estimates, data is provided for 2020 and 2021 (which serve as the historic years), for 2022 (the base year), and forecast for 2028.
Report Includes
41 data tables and 22 additional tables
Analysis of the PEGylated proteins market
Analyses of global market trends, with revenue data for 2021-2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2028
Estimates of the current market size and revenue growth prospects, along with a market share analysis by product and services, protein type, application, and region
Facts and figures pertaining to the market drivers, opportunities and restraints, and the impact of macroeconomic variables
An analysis of recent patent grants and published patents
A look at emerging technologies and regulatory issues
Overview of sustainability trends and ESG developments, including consumer attitudes, companies' ESG score rankings and their ESG practices
Insight into the competitive landscape, including companies' market shares, business segments, financials and product portfolios, as well as recent M&A activity and venture funding outlook
Profiles of the major market players
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Introduction
Advantages of Protein PEGylation
Limitations of PEGylated Therapeutics
Chapter 3 Market Dynamics
Market Dynamics Snapshot
Market Drivers
Protein Drugs in Hematology and Oncology
Design of Biobetters
Market Restraints
Immunogenicity and Side Effects
Formulation Challenges
Market Opportunities
Site-Specific PEGylation
New Indications and Formulation Techniques
Chapter 4 Emerging Technologies and Developments
Introduction
Non-Covalent PEGylation
PEGylation of Nanoparticles
Antibody-Drug Conjugates (ADCs)
Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Global PEGylated Proteins Market, by Protein Type
Granulocyte-Colony Stimulating Factors (G-CSF)
PEGylated Monoclonal Antibodies
PEGylated Interferons
PEGylated Recombinant Factors
Other Protein Types
Global PEGylated Proteins Market, by PEGylation Type
Linear PEGylated Proteins
Branched PEGylated Proteins
Global PEGylated Proteins Market, by PEGylation Application
Autoimmune Diseases
Hematology
Cancer
Other Applications
Geographic Breakdown
Global Market for PEGylated Proteins, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 6 Competitive Intelligence
Recent Developments in the PEGylated Proteins Market
Clinical Trial Activities
Chapter 7 Sustainability in the PEGylated Proteins Market: ESG Perspective